Global Beta Blockers Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
USD 9,576.09 million |
 Market Size (Forecast Year) |
USD 13,684.08 million |
 CAGR |
% |
| Major Markets Players |
>全球 β 受体阻滞剂市场，按药物（倍他洛尔、醋丁洛尔、艾司洛尔、阿替洛尔等）、适应症（心绞痛、心力衰竭、高血压等）、最终用户（医院、家庭护理、专科诊所等）、分销渠道（医院药房、网上药房和零售药房）划分 - 行业趋势和预测到 2030 年。
β受体阻滞剂市场分析和规模
由于技术进步、研发投入巨大、心血管疾病患病率和发病率高以及老龄化人口增加，β受体阻滞剂市场的需求大幅增加，这将推动市场增长。此外，患者人数增加和缺乏适当治疗将成为市场增长的机会。然而，治疗后并发症和某些药物停用可能会阻碍市场增长。
如果您患有高血压，不建议将β受体阻滞剂作为首选治疗方法。除非利尿剂等其他药物有效，否则通常不会为高血压开这些药物。此外，医生可能会开出β受体阻滞剂作为降低血压的所有几种药物之一。β受体阻滞剂对黑人和老年人可能没有那么有效，尤其是那些没有服用其他降压药的人。β受体阻滞剂用于预防、治疗或改善心律失常（心律失常）、心力衰竭、胸痛（心绞痛）、心脏病发作、偏头痛和某些类型的震颤患者的症状。
Data Bridge Market Research 分析称，2023 年 95.7609 亿美元的 Beta 受体阻滞剂市场到 2030 年将飙升至 136.8408 亿美元，预计在预测期内的复合年增长率为 5.2%。由于道路交通事故数量不断增加，“不完全脊髓损伤”在 Beta 受体阻滞剂市场类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
β受体阻滞剂市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按药物（倍他洛尔、醋丁洛尔、艾司洛尔、阿替洛尔等）、适应症（心绞痛、心力衰竭、高血压等）、最终用户（医院、家庭护理、专科诊所等）、分销渠道（医院药房、网上药房和零售药房） |
|
覆盖国家 |
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa |
|
Market Players Covered |
Pierre Fabre Group (France), ANI Pharmaceuticals, Inc.(U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), King Pharma (U.S.), Lupin (India), GlaxoSmithKline plc. (U.K.), Sun Pharmaceutical Industries Ltd.(India), Teva Pharmaceutical Industries Ltd.(Israel), and Amneal Pharmaceuticals LLC. (U.S.) among others. |
|
Market Opportunities |
|
Market Definition
The global beta blockers market refers to the market for pharmaceutical drugs known as beta-adrenergic receptor antagonists or beta blockers. It is a class of medications that block the action of adrenaline and other stress hormones on beta receptors in the body. They are primarily used to manage various cardiovascular conditions such as hypertension (high blood pressure), angina (chest pain), arrhythmias (irregular heart rhythms), and heart failure.
Global Beta Blockers Market Dynamics
Drivers
- Increasing Prevalence of Cardiovascular Diseases
The rising incidence of cardiovascular diseases, such as hypertension, angina, and arrhythmias, is a significant driver for the beta blockers market. As these conditions become more prevalent globally, the demand for effective medications such as beta blockers increases.
- Growing Geriatric Population
The aging population is prone to cardiovascular disorders, making them a significant consumer group for beta blockers. With the increasing number of elderly individuals worldwide, there is a higher demand for cardiovascular medications, including beta blockers.
- Increasing Awareness and Diagnosis
Improved cardiovascular health awareness and early diagnosis of related conditions contribute to the demand for beta blockers. With increased health consciousness among individuals and proactive healthcare initiatives, more patients are being diagnosed with cardiovascular diseases, leading to higher prescription rates for beta blockers.
Opportunities
- Advancements in Drug Formulations
Ongoing research and development efforts have led to the development of advanced formulations of beta blockers. These include extended-release formulations that offer a longer duration of action, improved patient compliance, and enhanced therapeutic outcomes. The availability of such innovative formulations acts as an opportunity for market growth.
Restraints/Challenges
- Side Effects and Adverse Reactions
Beta blockers can cause side effects such as fatigue, dizziness, low blood pressure, sexual dysfunction, and depression. These side effects may limit patient adherence to treatment and lead to medication discontinuation. Additionally, some individuals may experience severe adverse reactions, such as bronchospasm in patients with asthma or heart block in certain cardiac conditions, which can restrict the use of beta blockers in specific patient populations.
Recent Development
-
In June 2022, Eagle Pharmaceuticals, Inc. announced that it has submitted the new drug application to U.S. Food and Drug Administration for landiolol, a beta-1 adrenergic blocker, for approval
-
In April 2022, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.
Global Beta Blockers Market Scope
The Beta blockers market is segmented on the basis of drugs, indication, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Betaxolol
- Acebutolol
- Esmolol
- Atenolol
- Others
Indication
- Angina Pectoris
- Heart Failure
- High Blood Pressure
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Beta blockers Market Regional Analysis/Insights
The Beta blockers market is analysed and market size insights and trends are provided by country, drugs, indication, end user, and distribution channel as referenced above.
The countries covered in the Beta blockers market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
医疗保健基础设施增长安装基础和新技术渗透
β 受体阻滞剂市场还为您提供每个国家/地区资本设备医疗保健支出增长、β 受体阻滞剂市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对 β 受体阻滞剂市场的影响的详细市场分析。数据涵盖 2010-2020 年的历史时期。
竞争格局和 β 受体阻滞剂市场份额分析
β 受体阻滞剂市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对 β 受体阻滞剂市场的关注有关。
β受体阻滞剂市场的一些主要参与者包括：
- 皮尔法伯集团（法国）
- ANI Pharmaceuticals, Inc.（美国）
- Mylan NV（美国）
- 诺华公司（瑞士）
- King Pharma（美国）
- 鲁冰花（印度）
- 葛兰素史克公司（英国）
- 太阳制药工业有限公司 (印度)
- Teva Pharmaceutical Industries Ltd.（以色列）
- Amneal Pharmaceuticals LLC.（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
